Genetic and pharmacologic inhibition of EPHA2 promotes apoptosis in NSCLC

Journal of Clinical Investigation

Volumn 124, Issue 5, 2014, Pages 2037-2049

  Amato, Katherine R ^a   Wang, Shan ^b   Hastings, Andrew K ^b   Youngblood, Victoria M ^a   Santapuram, Pranav R ^a   Chen, Haiying ^c   Cates, Justin M ^b,d   Colvin, Daniel C ^e   Ye, Fei ^f   Brantley Sieders, Dana M ^b,d   Cook, Rebecca S ^a,d   Tan, Li ^g   Gray, Nathanael S ^g   Chen, Jin ^a,b,d,h  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d VANDERBILT INGRAM CANCER CENTER   (United States)

^e VANDERBILT UNIVERSITY   (United States)

^f VANDERBILT UNIVERSITY   (United States)

^g HARVARD MEDICAL SCHOOL   (United States)

^h VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPHRIN RECEPTOR A2; GENOMIC DNA; K RAS PROTEIN; PROTEIN BAD;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DEATH; CELL GROWTH; CELL VIABILITY; CONTROLLED STUDY; EPITHELIUM CELL; GENE DISRUPTION; GENE MUTATION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL SURVIVAL; HETEROGRAFTS; HUMANS; LUNG NEOPLASMS; MICE; MICE, KNOCKOUT; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; PROTEIN KINASE INHIBITORS; RECEPTOR, EPHA2; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA;

EID: 84899739937     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI72522     Document Type: Article

References (30)

1. Beer DG, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med. 2002;8(8):816-824.
2. Rohrbeck A, et al. Gene expression profiling for molecular distinction and characterization of laser captured primary lung cancers. J Transl Med. 2008;6:69.
3. Zhu CQ, et al. Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. J Clin Oncol. 2010; 28(29):4417-4424.
4. Ding L, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 2008;455(7216):1069-1075.
5. Kullander K, Klein R. Mechanisms and functions of Eph and ephrin signaling. Nat Rev Mol Cell Biol. 2002;3(7):475.
6. Pasquale EB. Developmental Cell Biology: Eph receptor signalling casts a wide net on cell behaviour. Nat Rev Mol Cell Biol. 2005; 6(6):462-475.
7. Pasquale EB. Eph-ephrin bidirectional signaling in physiology and disease. Cell. 2008;133(1):38-52.
8. Larsen AB, Pedersen MW, Stockhausen MT, Grandal MV, van Deurs B, Poulsen HS. Activation of the EGFR gene target EphA2 inhibits epidermal growth factor-induced cancer cell motility. Mol Cancer Res. 2007;5(3):283-293.
9. Brantley-Sieders DM, et al. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. J Clin Invest. 2008;118(1):64-78.
10. Brannan JM, et al. Expression of the receptor tyrosine kinase EphA2 is increased in smokers and predicts poor survival in non-small cell lung cancer. Clin Cancer Res. 2009;15(13):4423-4430.
11. Faoro L, et al. EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mTOR activation. J Biol Chem. 2010;285(24):18575-18585.
12. Kinch MS, Moore MB, Harpole DHJ. Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. Clin Cancer Res. 2003;9(2):613-618.
13. Zhuang G, et al. Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. Cancer Res. 2010;70(1):299-308.
14. Brantley-Sieders DM, et al. Eph/ephrin profiling in human breast cancer reveals significant associations between expression level and clinical outcome. PLoS One. 2011;6(9):e24426.
15. Fang WB, Brantley-Sieders DM, Parker MA, Reith AD, Chen J. A kinase-dependent role for EphA2 receptor in promoting tumor growth and metastasis. Oncogene. 2005;24(53):7859-7868.
16. Brantley-Sieders DM, Fang WB, Hicks D, Koyama T, Shyr Y, Chen J. Impaired tumor microenvironment in EphA2-deficient mice inhibits tumor angiogenesis and metastatic progression. FASEB J. 2005;19(13):1884-1886.
17. Johnson L, et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature. 2001;410(6832):1111-1116.
18. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell. 1996;87(4):619-628.
19. Harada H, Andersen JS, Mann M, Terada N, Korsmeyer SJ. p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proc Natl Acad Sci U S A. 2001; 98(17):9666-9670.
20. Choi Y, et al. Discovery and structural analysis of Eph receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2009;19(15):4467-4470.
21. Liu Y, Gray NS. Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol. 2006;2(7):358-364.
22. Dzamko N, et al. The IkappaB kinase family phosphorylates the Parkinson's disease kinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signaling. PLoS One. 2012;7(6):e39132.
23. Patricelli MP, et al. In situ kinase profiling reveals functionally relevant properties of native kinases. Chem Biol. 2011;18(6):699-710.
24. Macrae M, et al. A conditional feedback loop regulates Ras activity through EphA2. Cancer Cell. 2005;8(2):111-118.
25. Miao H, et al. EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt. Cancer Cell. 2009;16(1):9-20.
26. Brannan JM, et al. EphA2 in the early pathogenesis and progression of non-small cell lung cancer. Cancer Prev Res. 2009;2(12):1039-1049.
27. Brantley DM, et al. Soluble EphA receptors inhibit tumor angiogenesis and progression in vivo. Oncogene. 2002;21(46):7011-7026.
28. Chen J. Regulation of tumor initiation and metastatic progression by Eph receptor tyrosine kinases. Adv Cancer Res. 2012;114:1-20.
29. Brantley-Sieders D, Caughron J, Hicks D, Pozzi A, Ruiz JC, Chen J. EphA2 receptor tyrosine kinase regulates endothelial cell migration and assembly through phosphoinositide 3-kinasemediated Rac1 GTPase activation. J Cell Sci. 2004; 117(pt 10):2037-2049.
30. Patricelli MP, et al. Functional interrogation of the kinome using nucleotide acyl phosphates. Biochemistry. 2007;46(2):350-358.